Drugs / HIV-1 Tat
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00529698 | Jan 2004 → Nov 2007 | HIV infectious disease | Italian National Institute of Health | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HIV-1 Tat | “The native HIV-1 Tat protein was chosen as vaccine candidate for phase I clinical trials based on its role in the natural infection and AIDS pathogenesis” PMID 19879233 ↗ Oct 2009 |
| Known as | Tat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00529698 ↗ |
| Modality | Vaccine | “The native HIV-1 Tat protein was chosen as vaccine candidate for phase I clinical trials” PMID 19879233 ↗ Oct 2009 |
| Route | Subcutaneous | “Subjects were immunized subcutaneously with Tat” NCT00529698 ↗ |